Background Despite therapeutic advances in HER2-positive metastatic breast cancer,
resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the …

Apatinib is an oral, highly potent tyrosine‐kinase inhibitor targeting VEGFR2. Phase I study
showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase …

PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity
and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of …

Background Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth
factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of …

Background Tucidinostat (formerly known as chidamide) is an oral subtype-selective
histone deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with …

Blockade of the cyclin-dependent kinase 4 and 6 pathway has been shown to be effective in
the treatment of hormone receptor-positive advanced breast cancer (ABC). We report the …

Small molecules that can selectively target cancer stem cells (CSCs) remain rare currently
and exhibit no common structural features. Here we report a series of guaianolide …

Purpose Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal
growth factor receptor and human epidermal growth factor receptor 2 (HER2). This study is …

Extending the benefits of tumor molecular profiling for all cancer patients requires a
comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this …

LETTERS TO THE EDITOR 905 dematiaceous yeast-like cells, hyphae, and pseudohyphae
in tissue, while sclerotic bodies, characteristics of chromoblastomycosis, are absent. 1 …